跳至主要内容
临床试验/NCT00225706
NCT00225706已完成3 期

Efficacy and Safety Study of Caldolor in Hospitalized Febrile Pediatric Patients

Cumberland Pharmaceuticals6 个研究点 分布在 3 个国家开始时间: 2005年10月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
试验地点
6
主要终点
Temperature

研究概览

简要总结

The primary objective of this study of Caldolor administered to febrile hospitalized pediatric patients every 6 hours for 24 hours is to determine the clinical equivalence of a single dose of Caldolor compared to acetaminophen (paracetamol; APAP) for the treatment of fever as measured by the AUC Tº within the first 6 hours of treatment (as compared to a target temperature of 98.6ºF [37.0ºC]).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Be hospitalized
  • Be between 6 months and 17 years of age, inclusive
  • Have new (not chronic, within last 7 days) onset of fever, documented by temperature greater than or equal to 101.0ºF (38.3ºC) (The preferred method of temperature measurement is core. The route of temperature measurement used immediately before randomization should be used immediately before dosing and for all temperature measurements during the Treatment Period.)
  • Have written informed consent provided by legal parent, guardian, or authorized agent, and have same agree to abide by the study restrictions and to return for the required assessments (Where appropriate, participants of appropriate intellectual maturity should personally provide written informed assent; age of assent may be determined by Institutional Review Boards (IRBs) or Independent Ethics Committees (IECs) or be consistent with local legal requirements.)

排除标准

  • Have inadequate intravenous access
  • Have received antipyretic drug therapy within 8 hours before dosing
  • Be pregnant or nursing
  • Have any history of allergy or hypersensitivity to NSAIDs, aspirin, APAP, or any component of Caldolor or APAP.
  • Have a history of severe head trauma that required the current hospitalization, had intracranial surgery or stroke within the previous 30 days, or have any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesions
  • Have a history of febrile convulsion or have a sibling with a history of febrile convulsion
  • Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active clinically significant bleeding, or have underlying platelet dysfunction, including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
  • Have gastrointestinal bleeding that has required medical intervention within the previous 6 weeks, unless definitive surgery has been performed
  • Have platelet count less than 30,000/mm3
  • Be receiving full dose anticoagulation therapy (Prophylaxis with subcutaneous heparin is acceptable.)
  • Have fever secondary to blood or drug reaction
  • Have an expected life span of less than 14 days because of imminent withdrawal of life support or severity of illness
  • Be receiving ongoing or imminent treatment with corticosteroids
  • Have neurogenic fever
  • Be on dialysis, have oliguria or calculated creatinine clearance of less than 70 mL/min (calculated using the Schwartz formula), have impaired renal function, be receiving nephrotoxic drugs, or be expected to be unable to tolerate the extra fluid required for administration of CTM
  • Have had major surgery within the past 12 hours, unless adequate hemostasis has been achieved
  • Have received another investigational drug within the past 30 days
  • Be otherwise unsuitable for the study, in the opinion of the Investigator

结局指标

主要结局

Temperature

次要结局

未报告次要终点

研究者

发起方
Cumberland Pharmaceuticals
申办方类型
Industry

研究点 (6)

Loading locations...

相似试验